UNASSIGNED: To investigate if clinical trial enrollment following liquid biopsy CGP for non-small cell lung cancer (NSCLC) is clinically and/or economically impactful from a payer claims perspective.
UNASSIGNED: Clinical and economic outcomes were studied using a real-world clinical genomic database (including payer claims data) from patients with NSCLC who enrolled in clinical trials immediately following liquid biopsy CGP (using Guardant360) and matched NSCLC patient controls also tested with liquid biopsy CGP.
UNASSIGNED: Real-world overall survival was significantly (log-rank P < 0.0001) better for patients enrolled in clinical trials with similar costs of care, albeit with more outpatient encounters among those enrolled compared with matched controls.
UNASSIGNED: The results, together with previous analyses, suggest that, in addition to the clinical benefits associated with targeted therapies directed by CGP and other testing approaches, payers and specialty pharmacy managers may consider clinical trial direction and enrollment as a clinical and economic benefit of liquid biopsy CGP and adopt this into coverage decision frameworks and formularies.
■从付款人索赔的角度,调查非小细胞肺癌(NSCLC)液体活检CGP后的临床试验注册是否具有临床和/或经济影响。
■使用真实世界的临床基因组数据库(包括付款人索赔数据)研究了NSCLC患者的临床和经济结果,这些患者在液体活检CGP(使用Guardant360)和匹配的NSCLC患者对照也用液体活检CGP进行了测试。
■参加临床试验且护理费用相似的患者的真实世界总生存率显著提高(log-rankP<0.0001),尽管与匹配的对照组相比,这些参与者的门诊就诊次数更多。
■结果,加上以前的分析,建议,除了与CGP和其他测试方法指导的靶向治疗相关的临床益处外,付款人和专业药房经理可以将临床试验方向和注册视为液体活检CGP的临床和经济效益,并将其纳入承保决策框架和处方集。